JONATHAN PHILIP KALEHOFF
Prescription History 1356705693
Internal Medicine in Birmingham, AL

NPI Status: Active since April 13, 2016

Contact Information

625 19TH ST S
BIRMINGHAM, AL
ZIP 35233
Phone: (205) 934-2490

Get Directions

Prescription History for Informed Healthcare Decisions

Explore the verified Medicare Part D prescription history, volume metrics, and calculated drug costs for JONATHAN PHILIP KALEHOFF, an active Internal Medicine specialist practicing in Birmingham, AL. Our medical registry currently tracks 8 unique pharmaceutical formulations prescribed by this provider, representing an estimated volume of 156 documented patient claims. Among these therapy options, the most frequently utilized medication is Trelegy Ellipta, which accounts for 31 claims alone.


Albuterol Sulfate Hfa

Generic Formulation: Albuterol SulfateSpecialty: Internal Medicine
Provider Metrics Summary
Total Claims 22
30-Day Fills 29.2
Days Supply 876
AL State Average Benchmarks
Peer Average Claims72.0
Peer Average 30-Day Fills88.4
Peer Average Days Supply2,207
Highly Conservative Utilization

This provider demonstrates a highly selective approach to this formula, recording 69.4% less volume than the regional standard for practitioners inside AL. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $678.74 across this reporting matrix range.

Provider Avg Cost Per Claim

$30.85

State Avg Cost Per Claim

$48.06

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A short-acting beta-2 adrenergic agonist that is primarily used as a bronchodilator agent to treat ASTHMA. Albuterol is prepared as a racemic mixture of R(-) and S(+) stereoisomers. The stereospecific preparation of R(-) isomer of albuterol is referred to as levalbuterol.

Therapeutic Applications

Albuterol (also known as salbutamol) is used to treat wheezing and shortness of breath caused by breathing problems such as asthma. It is a quick-relief medication. Albuterol belongs to a class of drugs known as bronchodilators. It works by relaxing the muscles around the airways so that they open up and you can breathe more easily. Controlling symptoms of breathing problems can decrease time lost from work or school.

Anoro Ellipta

Generic Formulation: Umeclidinium Brm/Vilanterol TrSpecialty: Internal Medicine
Provider Metrics Summary
Total Claims 19
30-Day Fills 25.0
Days Supply 750
AL State Average Benchmarks
Peer Average Claims32.0
Peer Average 30-Day Fills40.7
Peer Average Days Supply1,217
Conservative Utilization

This provider writes prescriptions for this formulation 40.6% less frequently than the standard regional baseline metric for practitioners inside AL. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $11,908.01 across this reporting matrix range.

Provider Avg Cost Per Claim

$626.74

State Avg Cost Per Claim

$594.18

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

This product is used to control and prevent symptoms (such as wheezing and shortness of breath) caused by ongoing lung disease (chronic obstructive pulmonary disease-COPD, which includes chronic bronchitis and emphysema). Controlling symptoms of breathing problems helps you stay active. This inhaler contains 2 medications: umeclidinium and vilanterol. Both drugs work by relaxing the muscles around the airways so that they open up and you can breathe more easily. Umeclidinium belongs to a class of drugs known as anticholinergics. Vilanterol belongs to the class of drugs known as long-acting beta agonists (LABAs). Both drugs are also known as bronchodilators. This medication must be used regularly to be effective. It does not work right away and should not be used to relieve sudden shortness of breath. If sudden breathing problems occur, use your quick-relief inhaler as prescribed. Umeclidinium/vilanterol is not approved to treat asthma. People with asthma using long-acting inhaled beta agonists (such as vilanterol) without also using an inhaled corticosteroid may have an increased risk of serious (sometimes fatal) breathing problems.

Azithromycin

Generic Formulation: AzithromycinSpecialty: Internal Medicine
Provider Metrics Summary
Total Claims 16
30-Day Fills 18.0
Days Supply 540
AL State Average Benchmarks
Peer Average Claims53.0
Peer Average 30-Day Fills54.9
Peer Average Days Supply372
Highly Conservative Utilization

This provider demonstrates a highly selective approach to this formula, recording 69.8% less volume than the regional standard for practitioners inside AL. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $402.26 across this reporting matrix range.

Provider Avg Cost Per Claim

$25.14

State Avg Cost Per Claim

$10.06

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A semi-synthetic macrolide antibiotic structurally related to ERYTHROMYCIN. It has been used in the treatment of Mycobacterium avium intracellulare infections, toxoplasmosis, and cryptosporidiosis.

Therapeutic Applications

This medication is used to treat certain eye infections. It is a macrolide antibiotic that works by stopping the growth of bacteria. This medication treats only bacterial eye infections. It will not work for other types of eye infections. Unnecessary use or misuse of any antibiotic can lead to its decreased effectiveness.

Furosemide

Generic Formulation: FurosemideSpecialty: Internal Medicine
Provider Metrics Summary
Total Claims 16
30-Day Fills 18.0
Days Supply 444
AL State Average Benchmarks
Peer Average Claims101.0
Peer Average 30-Day Fills203.8
Peer Average Days Supply5,826
Highly Conservative Utilization

This provider demonstrates a highly selective approach to this formula, recording 84.2% less volume than the regional standard for practitioners inside AL. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $87.25 across this reporting matrix range.

Provider Avg Cost Per Claim

$5.45

State Avg Cost Per Claim

$6.19

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A benzoic-sulfonamide-furan. It is a diuretic with fast onset and short duration that is used for EDEMA and chronic RENAL INSUFFICIENCY.

Therapeutic Applications

Furosemide is used to reduce extra fluid in the body (edema) caused by conditions such as heart failure, liver disease, and kidney disease. This can lessen symptoms such as shortness of breath and swelling in your arms, legs, and abdomen. This drug is also used to treat high blood pressure. Lowering high blood pressure helps prevent strokes, heart attacks, and kidney problems. Furosemide is a water pill (diuretic) that causes you to make more urine. This helps your body get rid of extra water and salt.

Incruse Ellipta

Generic Formulation: Umeclidinium BromideSpecialty: Internal Medicine
Provider Metrics Summary
Total Claims 23
30-Day Fills 31.0
Days Supply 930
AL State Average Benchmarks
Peer Average Claims22.0
Peer Average 30-Day Fills26.2
Peer Average Days Supply766
Standard Average Utilization

This provider's prescribing patterns for this therapeutic formulation sit directly in line with standard baseline averages across AL. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $11,815.78 across this reporting matrix range.

Provider Avg Cost Per Claim

$513.73

State Avg Cost Per Claim

$432.61

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

Umeclidinium is used to control and prevent symptoms (such as wheezing, shortness of breath) caused by ongoing lung disease (chronic obstructive pulmonary disease-COPD, which includes bronchitis and emphysema). It works by relaxing the muscles around the airways so that they open up and you can breathe more easily. Umeclidinium belongs to a class of drugs known as anticholinergics. Controlling symptoms of breathing problems can decrease time lost from work or school. This medication must be used regularly to be effective. It does not work right away and should not be used to relieve sudden shortness of breath. If wheezing or sudden shortness of breath occurs, use your quick-relief inhaler (such as albuterol, also called salbutamol in some countries) as prescribed.

Ofev

Generic Formulation: Nintedanib EsylateSpecialty: Internal Medicine
Provider Metrics Summary
Total Claims 11
30-Day Fills 11.0
Days Supply 330
AL State Average Benchmarks
Peer Average Claims32.0
Peer Average 30-Day Fills32.5
Peer Average Days Supply973
Highly Conservative Utilization

This provider demonstrates a highly selective approach to this formula, recording 65.6% less volume than the regional standard for practitioners inside AL. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $148,445.17 across this reporting matrix range.

Provider Avg Cost Per Claim

$13,495.02

State Avg Cost Per Claim

$12,354.63

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

This medication is used to treat certain types of lung disease (idiopathic pulmonary fibrosis- IPF, interstitial lung disease). Both types of lung disease scar and stiffen your lungs, making it hard to breathe. Nintedanib may help slow down the worsening of your lung disease.

Symbicort

Generic Formulation: Budesonide/Formoterol FumarateSpecialty: Internal Medicine
Provider Metrics Summary
Total Claims 18
30-Day Fills 19.0
Days Supply 570
AL State Average Benchmarks
Peer Average Claims32.0
Peer Average 30-Day Fills44.5
Peer Average Days Supply1,334
Conservative Utilization

This provider writes prescriptions for this formulation 43.8% less frequently than the standard regional baseline metric for practitioners inside AL. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $7,506.91 across this reporting matrix range.

Provider Avg Cost Per Claim

$417.05

State Avg Cost Per Claim

$528.25

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A pharmaceutical preparation of budesonide and formoterol fumarate that is used as an ANTI-ASTHMATIC AGENT and for the treatment of CHRONIC OBSTRUCTIVE PULMONARY DISEASE.

Therapeutic Applications

This product is used to control and prevent symptoms (wheezing and shortness of breath) caused by asthma or ongoing lung disease (chronic obstructive pulmonary disease-COPD, which includes chronic bronchitis and emphysema). It contains 2 medications: budesonide and formoterol. Budesonide belongs to a class of drugs known as corticosteroids. It works by reducing the irritation and swelling of the airways. Formoterol belongs to the class of drugs known as long-acting beta agonists. It works by relaxing the muscles around the airways so that they open up and you can breathe more easily. Controlling symptoms of breathing problems can decrease time lost from work or school. When used alone, long-acting beta agonists (such as formoterol) may rarely increase the risk of serious (sometimes fatal) asthma-related breathing problems. However, combination inhaled corticosteroid and long-acting beta agonists, such as this product, do not increase the risk of serious asthma-related breathing problems. Before using this medication, it is important to learn how to use it properly. If an asthma attack occurs, use your quick-relief inhaler (such as albuterol, also called salbutamol in some countries) as prescribed. See also How to Use section.

Trelegy Ellipta

Generic Formulation: Fluticasone/Umeclidin/VilanterSpecialty: Internal Medicine
Provider Metrics Summary
Total Claims 31
30-Day Fills 35.0
Days Supply 1,050
AL State Average Benchmarks
Peer Average Claims62.0
Peer Average 30-Day Fills78.2
Peer Average Days Supply2,343
Conservative Utilization

This provider writes prescriptions for this formulation 50.0% less frequently than the standard regional baseline metric for practitioners inside AL. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $23,089.00 across this reporting matrix range.

Provider Avg Cost Per Claim

$744.81

State Avg Cost Per Claim

$818.55

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

This product is used to control and prevent symptoms (such as wheezing and shortness of breath) caused by asthma and ongoing lung disease (chronic obstructive pulmonary disease-COPD, which includes chronic bronchitis and emphysema). Controlling symptoms of breathing problems helps you stay active. This inhaler contains 3 medications: fluticasone, umeclidinium, and vilanterol. Fluticasone belongs to a class of drugs known as corticosteroids. It works by reducing swelling of the airways in the lungs to make breathing easier. Umeclidinium belongs to a class of drugs known as anticholinergics and vilanterol is a LABA medication. Both drugs work by relaxing the muscles around the airways so that they open up and you can breathe more easily. Both drugs are also known as bronchodilators. When used alone, long-acting beta agonists (such as vilanterol) may rarely increase the risk of serious (sometimes fatal) asthma-related breathing problems. However, combination products containing both an inhaled corticosteroid and long-acting beta agonist, such as this product, do not increase the risk of serious asthma-related breathing problems. For asthma treatment, this product should be used when breathing problems are not well controlled with two asthma-control medications (such as inhaled corticosteroid and long-acting beta agonist) or if your symptoms need combination treatment. This medication must be used regularly to be effective. It does not work right away and should not be used to relieve sudden shortness of breath. If sudden breathing problems occur, use your quick-relief inhaler as prescribed.

Dataset Methodology & CMS Source Information

This analytical profile maps public infrastructure records sourced directly from official **Centers for Medicare & Medicaid Services (CMS)** public data releases. The statistics above track documented pharmaceutical treatment trends assigned to beneficiaries specifically under federal public programs. Evaluating the prescriptive footprints of clinical practitioners like JONATHAN PHILIP KALEHOFF provides transparency into local medical care patterns within Birmingham, AL.

Key Learning Objectives for this Profile:

  • Prescribing Frequencies: Track and evaluate the volume metrics of specific brand-name and generic medical formulas chosen by this provider over time.
  • Clinical Focus Areas: Identify how the provider distributes therapeutic selections across medical care options to gain insight into their true day-to-day **Internal Medicine** practice concentrations.
  • Program Cost Awareness: Review the calculated total systemic drug costs and raw transactional volumes linked to these orders to better anticipate network insurance coverage structures.
  • Patient-Centered Evaluation: Cross-reference localized regional care comparisons to align practitioner habits directly with your proactive health maintenance goals.

Data Scope Exclusion & Limitations: The data elements presented above explicitly reflect prescription orders processed for Medicare beneficiaries during the year 2023. This informational profile does not aggregate prescription data for individuals utilizing private commercial health plans, state Medicaid coverage, or self-pay options. However, because medical decision-making remains highly consistent across clinical settings, this public registry provides a reliable proxy for understanding the general prescribing preferences and pharmaceutical care approach used by this provider.